The use of reduction and nucleation technologies in nanosize active pharmaceutical
ingredient (API) is as an enabling to bring improved drug products to the marketplace …

Many newly discovered drug molecules have low aqueous solubility, which results in low
bioavailability. One way to improve their dissolution is to formulate them as nanoparticles …

Pharmaceutical particle technology is employed to improve poor aqueous solubility of drug
compounds that limits in vivo bioavailability owing to their low dissolution rate in the …

Poor water solubility is an industry wide issue, especially for pharmaceutical scientists in
drug discovery and drug development. In recent years, nanoparticle engineering processes …

The conversion of drugs into drug nanoparticles (nano-drugs) represents a feasible method
to enhance bioavailability of otherwise sparingly soluble-drugs. Nano-drugs enhance …

A drug's aqueous solubility is defined as the ability to dissolve in a particular solvent, and it
is currently a major hurdle in bringing new drug molecules to the market. According to some …

According to industry studies, more than 30% of new chemical entities developed during
drug discovery efforts exhibit poor solubility characteristics, severely limiting their therapeutic …

The advances in the field of nanotechnology have revolutionized the field of delivery of
poorly soluble active pharmaceutical ingredients (APIs). Nanosized formulations have been …

Particle size reduction can be used for enhancing the dissolution of poorly water-soluble
drugs in order to enhance bioavailability. In nanosuspensions, the particle size of the drug is …

Poorly water-soluble drugs comprise the majority of new drug molecules. Nanoparticle
agglomerates, called NanoClusters, can increase the dissolution rate of poorly soluble …